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Introduction
　Kawasaki disease (KD) is the most common acquired 
heart disease of childhood; however, its etiology remains 
unknown despite extensive investigation for decades.1 KD 
shares many clinical features with superantigen (SA) dis-
eases, such as toxic shock syndrome (TSS) and scarlet fe-
ver.2 A number of bacterial pathogens, including, Staphylo-
coccus aureus,2,3 Streptococcus pyogenes,3 and Yersinia 
pseudotuberculosis4 cause KD-like illnesses and encode 
bacterial SAs (exotoxins).5 In addition, Epstein-Barr virus 
(EBV) and interferon-alpha induce an endogenous SA en-
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coded by human endogenous retrovirus (HERV)-K18,6 
which stimulates Vß7+ CD4+ T cells. EBV is another exam-
ple known to cause KD-like illness,7,8 and viral infections 
sometimes precede the onset of KD.9 SAs stimulate large 
populations of T cells expressing particular variable T cell 
receptor ß chain gene segments10. Interestingly, Abe et al. 
reported increased CD4+ T cells expressing particular T-cell 
receptors (TCR), Vß2 (responding to TSST-1), and Vß8 in 
KD.11,12 Although their study indicated that KD is an SA 
disease caused by TSST-1 or related SAs,13 no particular mi-
crobial exotoxin has been consistently associated with KD 
in subsequent studies. It is worthy of notice that 18 strains of 
gram-positive cocci found in the gut of KD patients have 
been shown to induce the expansion of Vß2+ T cells in vitro.14
　One of the most interesting clinical features of KD is 
Bacille Calmette-Guerin vaccine (BCG) inoculation site le-
sions.15 BCG is included in the national immunization pro-
gram in Japan and usually given to infants aged 3 to 6 
months. Erythema and crust formation at the BCG inocula-
tion site is not just a useful diagnostic tool for KD but also 
has implications for the pathogenesis of KD. Many research-
ers suspect a mycobacterial pathogen closely related to BCG 
as an etiological agent of KD.16,17 
　Other clinical features of interest include cervical lymph-
adenopathy and liver dysfunction.18,19 The former is the least 
common among the major criteria of KD, but is often ob-
served in EBV or other infections.18 The latter is considered 
to be one of the factors predicting unresponsiveness to in-
travenous immunoglobulin (IVIG).20 Although IVIG is ef-
fective against the development of coronary arterial lesions, 
it remains obscure how it works and is difficult to predict 
which patients may not respond to the therapy.
　We hypothesized that KD is a syndrome caused by sev-
eral different SAs, and that such etiological differences re-
sult in differences in clinical manifestations or responses to 
treatment. In this study we focused on two SAs: TSST-1, a 
representable microbial SA and an endogenous SA induced 
by type-1 interferon or EBV infection. 
Materials and Methods
Patients
　We conducted a prospective study between January 2007 
and March 2009. KD was diagnosed according to a guide-
line by the Kawasaki Disease Study Group (Ministry of 
Health, Labour and Welfare).21 Seventy KD patients (38 
males, 32 females) were recruited at Nagasaki University 
Hospital and Nagasaki Harbor Medical Center City Hospi-
tal during the study period. Patients who had already re-
ceived initial treatment at other hospitals were excluded. 
The patientsʼ mean age was 22.9±15.8 months, ranging 
from 2 to 76 months. We showed KD patientsʼ profile in 
Table 1.
　The Harada scoring system was used to evaluate the risk 
of coronary artery aneurysms.22 The standard therapy for 
KD patients consists of high-dose IVIG and oral adminis-
tration of aspirin (30 mg/kg) during the febrile period. Dur-
ing 2007–2008, a daily infusion of 400 mg of IVIG per kg 
for five consecutive days was given. During 2008–2009, 2 g 
of IVIG per kg over 24 hours was given.23 Patients with re-
fractory KD required an additional dose of IVIG (1–2 g/kg), 
immunosuppressive drugs, or plasma exchange.24 Only 11 
patients were treated with aspirin, 46 received scheduled 
IVIG therapy, and 13 patients with refractory KD received 
additional IVIG therapy. Cardiac complications included 
three patients with pericardial effusion, 10 with transient 
coronary dilatation (coronary diameter >3 mm) 25 or a hy-
perechoic lesion of the vascular wall, and one with mild 
coronary aneurysm. Patients treated with aspirin only had 
no cardiac complications.
　We recruited the following control subjects: 18 children 
(mean age 66.5±62.9 months, range 7 to 192 months) who 
were not suspected of any SA disease or vasculitic patho-
genesis (non-vasculitic patients, NVs), 7 patients (mean age 
73.4±32.5 months, range 20 to 114 months) with anaphylac-
toid purpura (AP), another systemic vasculitic syndrome of 
childhood, and two patients with neonatal TSS-like exan-
thematous disease (NTED), a typical SA disease26 The ma-
jority of NVs were patients who underwent cardiac cathe-
terization for congenital heart disease.
Gender (male : female)
Mean age (months) 
　　　 Age range
Treatment
　　　 no IVIG (only aspirin)
　　　 scheduled IVIG only
　　　 additional IVIG
Cardiac complications： 
　　　 cardiac effusion 
　　　 transient coronary dilatation










Table 1. Kawasaki disease patientsʼ profile
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Definitions of clinical manifestations
　Three selected clinical features, BCG inoculation site le-
sion, cervical lymphadenopathy, and liver dysfunction, were 
graded or defined. The BCG inoculation site lesion was de-
fined as positive when erythema and crust formation was 
observed at the inoculation site.15 Cervical lymphadenopa-
thy was defined as the presence of lymph node(s) with a di-
ameter of more than about 1.5 cm or easily palpable. Liver 
dysfunction was defined as serum alanine aminotransferase 
(ALT) over 100 IU/ml.20
 
Blood sample collection and flow cytometry
　Peripheral blood was collected into a tube containing 
EDTA on 4–6 days from onset (pretreatment phase), 8–9 
days from onset (post-treatment phase-1) and 10–14 days 
from onset (post-treatment phase-2). 
　Anti-CD4 R-phycoerythrin (PE) (CALTAG TM Laborato-
ries, Buckingham, UK) and anti-Vß2 or anti-Vß7 fluorescein 
isothiocyanate (FITC) (IMMUNOTECH, Marseille, France) 
were added to each 100 µl of the fresh whole blood. After a 
15-minute incubation on ice, lysing solution was added to 
lyse red blood cells. The remaining cells were washed with 
phosphate buffer saline (PBS) several times and resuspend-
ed in 1 ml of PBS. The FACScanTM system (Becton Dickin-
son, New Jersey, United States) was used to measure the 
proportion of Vß2+ cells or Vß7+ cells in CD4+ T cells. 
Statistical Analysis
　The statistical analysis was performed by t-test, paired t-
test and multiple linear regression analysis with the step-
wise method by using the JMP pro 10 software (SAS insti-
tute Inc., North Carolina, USA). 
　We analyzed differences in Vß2+ or Vß7+CD4+ T cells be-
tween KD patients and control subjects by t-tests, and time 
series in KD by paired t-tests. Next, we performed a uni-
variate analysis to compare gender, BCG inoculation site 
lesion, cervical lymphadenopathy, liver dysfunction, thera-
py, cardiac complication, and Harada score. We analyzed 
these factors by a multiple linear regression analysis with 
the stepwise method. The data were expressed as means ± 
standard deviation. 
Ethics
　This study was approved by the Ethical committee of Na-
gasaki University School of Medicine.
Results
Comparison of Vß2 and Vß7 expression in CD4+ T cells be-
tween KD patients and control subjects
　In the pretreatment phase, the rates of Vß2+CD4+ T cells 
were not different between KD patients (9.9±2.9%)27 and 
NVs (9.0±1.8%), slightly lower in AP patients (6.6±1.8%), 
and much higher in NTED patients (25.2, 16.9) (Table 2). 
The rates of Vß7+CD4+ T cells were not significantly differ-
ent between KD patients and control groups. 
　The rates of Vß2+CD4+T cells in KD patients did not sig-
nificantly change throughout the pretreatment (4-5 days af-
ter onset), post-treatment-1 (8–9 days after onset) and post-
treatment-2 (10–14 days after onset) phases. On the other 
hand, the rates of Vß7+CD4+ T cells in KD patients were 
slightly higher in the pretreatment phase (2.8±1.1) than in 
the post-treatment-2 phase (2.5±0.6)  (p <0.05). 
Comparison of Vβ2 and Vβ7 expression in CD4+ T cells 
between subgroups of KD patients
　We subdivided KD patients according to selected clinical 




















NVs; Children who were not suspected of any SA disease or vasculitic pathogenesis Multiple 
comparison between the top three groups
In Vß2, a) KD vs Anaphylactoid purpura, p< 0.01, b) NVs vs Anaphylactoid purpura, p< 0.05 
Table 2. Vß2 and Vß7 expression levels in CD4+ T cells from children in various 
health conditions
b）〕a）〕
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Vß7 expression levels in CD4+ T cells (Table 3). Among se-
lected clinical features, only the presence of BCG inocula-
tion site lesion was associated with increased Vß2 expres-
sion in the pretreatment phase. When 39 KD patients with 
and 29 without BCG inoculation site lesions were compared, 
the rates of Vß2+CD4+ T cells in the pretreatment phase 
were significantly higher in the former (10.8±3.2%) than in 
the latter (8.8±2.1%). (p < 0.01) And the rates of Vß2+CD4+ 
T cells in KD patients with BCG inoculation site lesion 
(10.8±3.2) were also higher than in NVs (9.0±1.8%). (p < 
0.05) KD patients with BCG inoculation site lesions 
(17.2±10.2 months) were younger than those without them 
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 9.8 ± 2.8
10.8 ± 3.2
 8.8 ± 2.1
 9.5 ± 3.4
10.0 ± 2.8
 9.6 ± 2.6
10.1 ± 3.0
 9.9 ± 2.6
 9.9 ± 3.2
10.0 ± 2.2
10.5 ± 3.4
 9.8 ± 2.8


















1) Two patients who had not been immunized with BCG were excluded. Vß2 with BCG inoculation site present vs absent, 
　p < 0.01. Age with BCG inoculation site present vs absent, p < 0.001
2) Age with cervical lymphadenopathy present vs absent, p < 0.001
Table 4. Estimated parameters and multiple linear regression analysis contributing Vß2 expression 
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(32.0±17.7 months), and those with cervical lymphadenopa-
thy (36.4±15.8 months) were older than those without it 
(20.1±14.4 months). 
　Next, we examined expression levels of Vß2 and Vß7 in 
association with responsiveness to treatment or cardiac 
complications (Table 3). There was no significant difference 
in their expression levels.
　Stepwise multivariate linear regression analysis with el-
evation of Vß2 expression as a dependent variable revealed 
significant correlations with positive or negative BCG in-
oculation site lesion (Table 4). There was no difference in 
Vß7 expression in CD4+ T cells between the two subgroups. 
On the other hand, neither cervical lymphadenopathy nor 
liver dysfunction was associated with increases in Vß2 or 
Vß7 expression levels. 
Disscussion
　Many investigators have advocated KD as a syndrome 
that involves various etiologies and genetic factors.28,29,30 
Natividad et al. have recently hypothesized involvement of 
both superantigen and genetic factors in KD.31 The hypoth-
esis that KD is an SA disease has attracted many research-
ers, and a number of studies report expansion of CD4+ T 
cells expressing a particular T-cell receptor(s), implying ac-
tivation by a SA(s). In particular, expansion of Vß2+ cells by 
stimulation with TSST-1 has been shown by several studies, 
and is strengthened by the following results: (1) isolation of 
TSST-1 secreting S. aureus from the throat, rectum, axillar, 
and groin of KD patients,2 and (2) apparent protection of 
young infants from KD by maternally transferred neutral-
izing antibody against TSST-1.32
　Our data showed expansion of Vß2+CD4+ T cell popula-
tion at pretreatment in KD patients with erythematous BCG 
inoculation site lesion, but not those with cervical lymph-
adenopathy or liver dysfunction. This is the first report to 
investigate the association of the T cell repertoires with the 
respective clinical characteristics of KD. 
　It is not clear why expansion of the Vß2+CD4+ T cell pop-
ulation was modest as compared to NTED, a typical SA dis-
ease26 and why positive BCG inoculation site lesion was as-
sociated with expansion of the Vß2+CD4+ T cell population. 
It is apparent that not only TSST-1 producing Staphylococci 
but also other microorganisms are capable of inducing 
Vß2+CD4+ T cell population. Yamashiro and colleagues 
have recently identified Vβ2+CD4+T cells infiltrating in the 
jejunal mucosa and superantigenic exotoxins produced by 
bacteria colonizing the small intestinal mucosa of KD pa-
tients.14,33 There must be several unknown microorganisms 
producing an agent(s) inducing Vß2+CD4+T cells, although 
much less efficiently than TSST-1. Positive BCG inoculation 
site lesion has been associated with human heat shock pro-
tein (HSP) 63.16 It has also been reported that T cells ob-
tained from KD patients recognized an epitope from HSP65 
and cross-reacted with the corresponding peptide sequence 
of human HSP63.34 Since HSP65 was reported to be a mark-
er of coronary heart disease,35,36  it may also involve cardiac 
complications of KD. We hypothesize that a subgroup of 
KD is involved in a microbial agent(s) that express an SA to 
stimulate Vß2+CD4+T cells and have a homologue of 
HSP63. 
　Although we hypothesize that expansion of Vß2+CD4+T 
cell population is associated with acute-phase immunop-
athogenesis of this specific subgroup of KD, the rates of the 
Vß2+CD4+T cells did not significantly change throughout 
the clinical course in this study. It is possible that observa-
tion period (up to 10-14 days from the onset) in this study 
was shorter than in other reports11, 12 and might not be long 
enough to confirm settling down of these cell population.
　In contrast, KD patients with severe clinical features, 
cardiac complications or high Harada scores did not exhibit 
expansion of the Vß2+CD4+T cell population (Table 3). 
Thus, expansion of the Vß2+CD4+T cell population is char-
acteristic of only a subgroup of KD with positive BCG site 
lesion and not of all KD patients, suggesting that KD is im-
munopathologically heterogeneous and that risk factors for 
development of KD and those for its progression to more 
severe forms with cardiac complications may be different. 
　Expansion of the Vß7+CD4+T cell population was not ob-
served in KD patients. These cells population may be in-
duced by EBV or interferon-alpha through expression of 
endogenous SA, and their relation to KD were unknown. 
Interestingly, a previous study showed expansion of 
Vß7+CD8+T cells, but not of Vß2+CD4+ T cells in KD pa-
tients37. Further studies may be needed to clarify the in-
volvement of endogenous SA or its inducers such as EBV in 
the immunopathogenesis of KD.
Study limitation
　The standard IVIG therapy for KD was changed in 2008; 
previously, 400 mg of IVIG per kg was given for 5 consecu-
tive days, but a single IVIG infusion of 2 g per kg was given 
thereafter. Since the single IVIG infusion therapy was more 
effective to decrease cardiac complications, incidence of 
cardiac complications decreased during the latter half of the 
study period. 
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